Seres Therapeutics EPS of $0.47, revenue of $0.74M beats by $0.56M
Seres Therapeutics reported an EPS of $0.47 and revenue of $0.74M, which is $0.56M higher than expected, confirming a positive catalyst.
The current closing price of $4.64 is positioned just above the support level of $4.59 suggested by REPORTING, and the trading volume is low at 0.43 times the 20-day average, with the moving averages not aligned. Therefore, we considered entering the position with the expectation of a rebound near the support level.
If I currently buy at around $5.0, I will take profit at $8.1 (resistance level) if the price rises to $8.10, and I will cut losses at $4.59 (support level) if it falls to $4.59. These criteria are based on the resistance and support levels presented by REPORTING.
RSI(14)=45.1 (neutral), moving averages are not aligned, trading volume is 0.43 times the 20-day average (low), recent 7-day volatility +5.7% (slight increase) – Overall, there are no strong buy signals, and the low trading volume and misalignment are acting as warning signs.
There are no direct comparable cases, and no past cases have been provided for reference.
The forecast anticipated a 1.5% increase, but the actual result was a -10.9% loss, marking a failure. While the positive factors of EPS and revenue surprises, as well as the setting of target and stop-loss prices, were reasonable, the oversight of the RSI being at a neutral level, the trading volume being only 0.43 times the 20-day average, and the misalignment of moving averages were significant. Ignoring these bearish signals was a major cause of the loss.
In the next trades, even if there are positive factors, the priority will be to review trading volume and the alignment of moving averages. If low trading volume is confirmed, entry will be postponed or position size will be reduced, and the stop-loss will be set slightly above the current support level (e.g., $4.70) to limit risk. Additionally, the conditions will be strengthened to only enter when all technical signals are positive.